We are studying a combination of medications for patients with BRAF V600E-mutant metastatic colorectal cancer. The goal is to see if this combination works better than pembrolizumab alone.
Health conditions and diseases that the clinical trial is designed to study and treat.
Metastatic colorectal cancer occurs when cancer from the colon or rectum spreads to other parts of the body. This type of cancer can be characterized by high microsatellite instability (MSI-H) or mismatch repair deficiency (dMMR), which may affect treatment options.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.
